perampanel + placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson's Disease
Conditions
Parkinson's Disease
Trial Timeline
Oct 1, 2007 → Dec 1, 2008
NCT ID
NCT00566462About perampanel + placebo
perampanel + placebo is a phase 2 stage product being developed by Eisai for Parkinson's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00566462. Target conditions include Parkinson's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02220972 | Approved | Withdrawn |
| NCT01618695 | Phase 3 | Completed |
| NCT01161524 | Phase 2 | Completed |
| NCT00566462 | Phase 2 | Terminated |
Competing Products
20 competing products in Parkinson's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| 2 mg perampanel + 4 mg perampanel + placebo comparator | Eisai | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | 52 |
| Istradefylline 20 mg or 40 mg | Kyowa Kirin | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | 77 |
| Perampanel | Eisai | Phase 2 | 52 |